SAMHD1 and diffuse large B-cell lymphoma: In this regard, we found that SAMHD1 is differentially expressed in DLBCL cells and that low SAMHD1 expression or degradation with VLPs containing Vpx or siRNA-mediated depletion is associated with greater sensitivity to DSB-inducing agents doxorubicin and Veliparib, providing evidence that SAMHD1 mediates resistance to doxorubicin and Veliparib in DLBCL, and that the use of VLPs with Vpx to degrade SAMHD1 may be a potential therapeutic strategy to augment the efficacy of doxorubicin-based therapy in DLBCL.